Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Status:
Completed
Trial end date:
2017-02-16
Target enrollment:
Participant gender:
Summary
IMCgp100 is a new biological therapy designed for the treatment of melanoma skin cancer. The
drug is designed to target melanoma cells and stimulate immune cells to kill them. This trial
is designed to establish the level of drug that can be given to a patient that is tolerable.
It also designed to establish the best dosing schedule for the drug and to look for signals
that the drug is working as intended.